The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell us?

Just in case you were look­ing for more ev­i­dence of just how im­por­tant Am­gen’s patent win on En­brel is for the com­pa­ny and its in­vestors, Eval­u­atePhar­ma has come up with a for­ward-look­ing con­sen­sus es­ti­mate on what the list of top 10 drugs will look like in 2024.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.